TY - JOUR T1 - 2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints JO - Annals of Oncology UR - http://dx.doi.org/10.1016/j.annonc.2023.09.2826 PY - 2023/10/01 AU - Jackson-Spence F AU - Marin AP AU - Puente J AU - Molina-Cerrillo J AU - Hussain SA AU - Ackerman C AU - Bonsu N AU - Kelly J AU - Loriot Y AU - Powles TB AU - Pulido EG ED - DO - DOI: 10.1016/j.annonc.2023.09.2826 PB - Elsevier BV VL - 34 SP - S1224 EP - S1225 Y2 - 2025/07/13 ER -